Novan is a clinical development-stage biotechnology company focused on utilizing nitric oxide's naturally occurring anti-viral, anti-bacterial, anti-fungal and immunomodulatory mechanisms of action to treat a range of diseases with unmet needs. Co.'s product candidates are: SB204, a once-daily, topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails; and SB414, a topical cream-based product candidate for the treatment of inflammatory skin diseases. The NOVN stock yearly return is shown above.
The yearly return on the NOVN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the NOVN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|